XML 45 R11.htm IDEA: XBRL DOCUMENT
v3.3.0.814

Balance Sheet Components | 9 Months Ended
--- | ---
Sep. 30, 2015
Organization Consolidation And Presentation Of Financial Statements [Abstract] |
Balance Sheet Components |
4. | Balance Sheet Components
Cash and Cash Equivalents Cash and cash equivalents consisted of the following (in thousands):
|  | September 30, 2015 |  |  | December 31, 2014 |
Cash |  | $ | 95,488 |  |  | $ | 151,653 |
Certificates of deposits |  |  | 8,468 |  |  |  | — |
Money market funds |  |  | 104,694 |  |  |  | 13,802 |
Total cash and cash equivalents |  | $ | 208,650 |  |  | $ | 165,455 |
Investments All investments are classified as available-for-sale. The amortized cost, gross unrealized holding gains or losses, and fair value of our available-for-sale investments by major investments type are summarized in the tables below (in thousands):
|  | September 30, 2015 |
|  | Amortized Cost |  |  | Gross Unrealized Holding Gains |  |  | Gross Unrealized Holding Losses |  |  | Estimated Fair Value |
Corporate bonds |  | $ | 132,302 |  |  | $ | 316 |  |  | $ | (179 | ) |  | $ | 132,439 |
Certificated of deposits |  |  | 8,217 |  |  |  | 5 |  |  |  | — |  |  |  | 8,222 |
Equity investments |  |  | 124 |  |  |  | 62 |  |  |  | — |  |  |  | 186 |
Total investments |  | $ | 140,643 |  |  | $ | 383 |  |  | $ | (179 | ) |  | $ | 140,847 |
|  | December 31, 2014 |
|  | Amortized Cost |  |  | Gross Unrealized Holding Gains |  |  | Gross Unrealized Holding Losses |  |  | Estimated Fair Value |
Corporate bonds |  | $ | 158,692 |  |  | $ | 254 |  |  | $ | (514 | ) |  | $ | 158,432 |
Equity investments |  |  | 124 |  |  |  | 77 |  |  |  | — |  |  |  | 201 |
Total investments |  | $ | 158,816 |  |  | $ | 331 |  |  | $ | (514 | ) |  | $ | 158,633 |
At September 30, 2015, all of the available-for-sale investments had contractual maturities within four years. We periodically review our available-for-sale investments for other-than-temporary impairment. We consider factors such as the duration, severity and the reason for the decline in value, the potential recovery period and our intent to sell. For debt securities, we also consider whether (i) it is more likely than not that we will be required to sell the debt securities before recovery of their amortized cost basis, and (ii) the amortized cost basis cannot be recovered as a result of credit losses. During the quarters and nine months ended September 30, 2015 and 2014, we did not recognize any other-than-temporary impairment loss. At September 30, 2015, a total of $29.2 million of our cash and cash equivalents were held outside of the U.S. in our foreign subsidiaries to be used primarily for our China operations. Accrued Liabilities Accrued liabilities consisted of the following (in thousands):
|  | September 30, 2015 |  |  | December 31, 2014 |
Preclinical and clinical trial accruals |  | $ | 24,388 |  |  | $ | 25,418 |
Payroll and related accruals |  |  | 11,480 |  |  |  | 15,608 |
Professional services |  |  | 1,764 |  |  |  | 2,401 |
Other |  |  | 4,142 |  |  |  | 5,558 |
Total accrued liabilities |  | $ | 41,774 |  |  | $ | 48,985 |

X
- References No definition available. + Details
Name: | us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity. + References No definition available. + Details
Name: | us-gaap_SupplementalBalanceSheetDisclosuresTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration